echemi logo
  • Product
  • Supplier
  • Inquiry
    Home > Active Ingredient News > Drugs Articles > Top10 in the first quarter of financing transactions completed, pharmaceutical-related industries accounted for 3

    Top10 in the first quarter of financing transactions completed, pharmaceutical-related industries accounted for 3

    • Last Update: 2020-06-16
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit
    Pharmaceutical Network Industry Dynamics: In the first quarter of 2020, RMB financing volume fell to 541, down about 46.7% from the same period in the first quarter of 2019It is worth noting that in the number of domestic financing transactions completed TOP10, there are 3 pharmaceutical-related industries, of which biotechnology and pharmaceutical with 41 ranked first; Three industries completed a total of 70 financing transactions, accounting for 12.9% of the total amount of financing transactions, performance is bright.
    Among them, in the field of biopharmaceuticals, two pharmaceutical companies have raised more than 2 billion yuan, namely Kelelion and Hualan BiovaccinesIn a february 16 thin-night announcement, The Company disclosed plans for a non-public offering of shares for 2020The Company intends to issue no more than 18.7 million shares in a non-public offering, with an issue price of 123.56 yuan/share, and a total amount of capital raising not exceeding 2.311 billion yuan, after deducting the issuance fee, the full amount of funds shall be used to supplement the working capital.
    Gaoying Capital intends to subscribe in cash for all shares of this non-public offering, including the HCM China Fund, which is managed by GaoGao Capital Management Co., LtdUpon completion of this fixed increase, GaoYuCapital will become a shareholder of more than 5% of Kelley's holdings.
    Data show that Kelelion Pharmaceuticals is a global industry leader CDMO solution provider, mainly committed to the global pharmaceutical technology innovation and commercial application, for domestic and foreign large and medium-sized pharmaceutical enterprises, biotechnology enterprises to provide drug research and development, production of one-stop CMC services, has formed a service system including innovative drug CMC services, MAH business, preparation research and development production, clinical trial services, biological sample testing and drug registration and declaration services.
    March 27 news, Hualan Biological Vaccines, a vaccine business company of Hualan Biovaccines completed a strategic investment of 2.07 billion yuan financing, the investors are Gaoyu Capital (lead investment), Morningside Fund.
    Data show that Hualan Biovaccines is a controlling subsidiary of Hualan Bioengineering Co., Ltd., the main vaccine business, mainly developing and producing high-tech products such as bacterial vaccines, viral vaccines and genetically engineered vaccines for human useAccording to incomplete statistics, as of March 27, Hualan biovaccines in the field of medical health this year a total of 31 financing.
    However, industry analysis pointed out that in the first quarter of 2020, the number of transactions in which various capitals invest in China's biopharmaceutical industry is large, but the concentration of investment is relatively low, the amount of financing received by individual enterprises is not very prominent, the amount of investment is more scattered.
    Since this year, cell detection, bioanalysis and other technologies are also highly valued, a number of related biopharmaceutical companies such as JieYi Biological son in the first quarter have been financed.
    In March 2020, Hangzhou Jieyi Bio announced the completion of nearly 100 million yuan Of Pre-A round of financing, this financing for the first round of financing since the establishment of Jieyi Bio, the financing will be used for the pathogen macro genome mNGS-related equipment and kits registration certificate, testing service network construction.
    According to the data, Jie Yi Bio was founded by DrWang Wei, a founding member of Berry Gene, and Zhong Jie, a former partner of Zhejiang Big Health Industry Fund, and is a technology platform based on high-throughput sequencing (NGS) and gene editing (CRISPR/Cas) Its product innovation and data-driven combination, committed to the innovation of infectious disease testing future of the new technology companies, is the domestic supply of pathogen macro genome mNGS fully automatic testing product solutions companies.
    This article is an English version of an article which is originally in the Chinese language on and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to with relevant evidence.